Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
8.98
-0.58 (-6.07%)
Mar 31, 2025, 1:15 PM EDT - Market open
Entrada Therapeutics Revenue
In the year 2024, Entrada Therapeutics had annual revenue of $210.78M with 63.38% growth. Entrada Therapeutics had revenue of $37.40M in the quarter ending December 31, 2024, a decrease of -10.63%.
Revenue (ttm)
$210.78M
Revenue Growth
+63.38%
P/S Ratio
1.69
Revenue / Employee
$1,151,814
Employees
183
Market Cap
319.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TRDA News
- 7 days ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - GlobeNewsWire
- 5 weeks ago - Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
- 2 months ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Azenta Announces the Election of Dipal Doshi to its Board of Directors - PRNewsWire
- 3 months ago - Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire